Specific group of patients with impaired immunity invited in October for third COVID-19 vaccination From 6 October on, a specific group of people with severely impaired immunity (immunocompromised patients) will receive their invitation for a third vaccination against COVID-19.
RIVM welcomes German Federal Centre for Health Education Today RIVM’s Centre for Healthy Living (CGL) welcomes the Bundeszentrale für gesundheitliche Aufklärung.
Scientific background information on rubber granulate now available in English In December 2016, RIVM published in Dutch the results of its research into the health risks of playing sports on synthetic turf pitches with rubber granulate.
Environmentally harmful pharmaceuticals cannot be replaced yet RIVM investigates how the impact of pharmaceutical residues on the environment may be reduced.
Off-label use of medicinal products in the European Union Off-label use of medicinal products in the European Union is common, both in primary and in secondary care.
Learn how students can contribute to research from NASA, KNMI, RIVM and WUR The Global Learning and Observation to Benefit the Environment (GLOBE) program in the Netherlands (GLOBE Netherlands) is organising the annual GLOBE day on 21 March .
Age and vaccination history affect immune responses after natural infection with whooping cough Age plays a role in immune responses after a natural infection with Bordetella pertussis, the bacterium that causes the contagious respiratory infection pertussis (whooping cough).
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.